Perrigo Co. Plc (PRGO)
15.75
-0.03
(-0.19%)
USD |
NYSE |
Nov 02, 16:00
15.78
+0.03
(+0.19%)
Pre-Market: 20:00
Perrigo Net Income (Quarterly) : 88.50M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 88.50M |
| March 31, 2026 | -389.90M |
| December 31, 2025 | -1.414B |
| September 30, 2025 | 12.70M |
| June 30, 2025 | -0.50M |
| March 31, 2025 | 0.10M |
| December 31, 2024 | -41.40M |
| September 30, 2024 | -17.60M |
| June 30, 2024 | -105.70M |
| March 31, 2024 | 4.10M |
| December 31, 2023 | -27.70M |
| September 30, 2023 | 15.40M |
| June 30, 2023 | 8.90M |
| March 31, 2023 | -1.10M |
| December 31, 2022 | -12.70M |
| September 30, 2022 | -52.10M |
| June 30, 2022 | -64.90M |
| March 31, 2022 | -1.30M |
| December 31, 2021 | 32.10M |
| September 30, 2021 | -53.90M |
| June 30, 2021 | -111.90M |
| March 31, 2021 | 2.80M |
| December 31, 2020 | -52.20M |
| September 30, 2020 | -154.60M |
| June 30, 2020 | 12.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 57.60M |
| December 31, 2019 | -19.00M |
| September 30, 2019 | 92.20M |
| June 30, 2019 | 9.00M |
| March 31, 2019 | 63.90M |
| December 31, 2018 | 81.40M |
| September 30, 2018 | -67.50M |
| June 30, 2018 | 36.20M |
| March 31, 2018 | 80.80M |
| December 31, 2017 | 73.20M |
| September 30, 2017 | 44.50M |
| June 30, 2017 | -69.60M |
| March 31, 2017 | 71.60M |
| December 31, 2016 | -1.359B |
| September 30, 2016 | -1.590B |
| June 30, 2016 | -534.30M |
| March 31, 2016 | -529.20M |
| December 31, 2015 | -107.00M |
| September 30, 2015 | 260.90M |
| June 30, 2015 | -22.20M |
| March 31, 2015 | -22.20M |
| June 30, 2014 | 131.90M |
| March 31, 2014 | 48.10M |
| December 31, 2013 | -86.00M |
| September 30, 2013 | 111.40M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 6.451B |
| Merck & Co., Inc. | 5.067B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.023B |
| Total Expenses (Quarterly) | 934.30M |
| EPS Diluted (Quarterly) | 0.5337 |
| Enterprise Value | 5.244B |
| Gross Profit Margin (Quarterly) | 30.73% |
| Profit Margin (Quarterly) | 8.65% |
| Earnings Yield | -79.43% |
| Operating Earnings Yield | 12.16% |
| Normalized Earnings Yield | -21.84 |